Alpine Immune Sciences (NASDAQ:ALPN) Now Covered by Analysts at Morgan Stanley

Morgan Stanley started coverage on shares of Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) in a research note issued to investors on Thursday, The Fly reports. The firm set an “overweight” rating and a $17.00 price target on the biotechnology company’s stock. Morgan Stanley’s target price indicates a potential upside of 96.99% from the company’s current price.

Other equities research analysts have also issued research reports about the stock. SVB Leerink started coverage on shares of Alpine Immune Sciences in a report on Monday, November 21st. They issued an “outperform” rating and a $15.00 price target on the stock. Oppenheimer lowered their target price on shares of Alpine Immune Sciences from $17.00 to $14.00 and set an “outperform” rating on the stock in a report on Monday, October 24th. Finally, HC Wainwright lowered their target price on shares of Alpine Immune Sciences from $21.00 to $8.00 in a report on Monday, October 24th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Alpine Immune Sciences currently has an average rating of “Buy” and an average target price of $15.80.

Alpine Immune Sciences Price Performance

Shares of Alpine Immune Sciences stock opened at $8.63 on Thursday. The firm has a market capitalization of $262.36 million, a PE ratio of -4.82 and a beta of 1.28. The company’s fifty day moving average price is $6.95 and its two-hundred day moving average price is $7.38. Alpine Immune Sciences has a 52-week low of $4.82 and a 52-week high of $10.30.

Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) last announced its quarterly earnings results on Monday, November 14th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.32). The business had revenue of $8.37 million during the quarter, compared to the consensus estimate of $20.43 million. Alpine Immune Sciences had a negative net margin of 169.92% and a negative return on equity of 41.76%. Analysts predict that Alpine Immune Sciences will post -1.59 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Alpine Immune Sciences

Large investors have recently made changes to their positions in the company. Monashee Investment Management LLC bought a new stake in shares of Alpine Immune Sciences in the 3rd quarter worth about $720,000. Caas Capital Management LP bought a new stake in Alpine Immune Sciences during the 3rd quarter worth about $327,000. Commodore Capital LP bought a new stake in Alpine Immune Sciences during the 3rd quarter worth about $9,540,000. Lynx1 Capital Management LP grew its holdings in Alpine Immune Sciences by 58.6% during the 3rd quarter. Lynx1 Capital Management LP now owns 3,056,420 shares of the biotechnology company’s stock worth $22,006,000 after acquiring an additional 1,129,551 shares during the last quarter. Finally, RA Capital Management L.P. bought a new stake in Alpine Immune Sciences during the 3rd quarter worth about $31,368,000.

About Alpine Immune Sciences

(Get Rating)

Alpine Immune Sciences, Inc is a development-stage pharmaceutical company, which engages in the discovery of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. Its product pipeline includes inflammatory diseases, immuno-oncology, and engineered cellular therapies.